利妥昔与DC-CIK治疗ALL患儿的疗效及预后影响分析

Clinical effect analysis of Rituximab combined with DC-CIK in treating childhood acute lymphoblastic leukaemia

目的研究利妥昔配合DC-CIK治疗儿童前体B型急性淋巴细胞白血病(ALL)的疗效及不良反应,重点分析利妥昔对DC-CIK治疗后的影响。方法回顾分析2006年6月-2012年6月四川省遂宁市中心医院50例CD20阳性的ALL患儿,分为对照组和观察组,每组25例。对照组采用化疗配合DC-CIK治疗;观察组采用利妥昔、化疗和DC-CIK联合治疗的方法。比较两组患儿治疗后的临床疗效及不良反应,并统计随访中两组患儿的3年无事件生存率。结果治疗后两组患儿Per2、Bmal1及EVI1 mRNA比较,差异有统计学意义(P<0.05),表达下降,且观察组低于对照组。观察组与对照组比较,治疗后临床疗效略好,但其不良反应较多。观察组患儿3年无事件生存率高于对照组。结论利妥昔配合DC-CIK治疗疗效更佳,利妥昔对DC-CIK预后有促进作用,但其治疗后副作用较多且费用较高。

Objective To investigate efficacy and adverse effects of rituximab combined with DC-CIK in treating childhood pre B acute lymphocytic leukemia(ALL),and to analyze the effect of rituximab on the prognosis of DC-CIK.Methods Retrospective analysis was used to select 50 ALL patients with CD20 positive in our hospital during June 2006 to June 2012.The patients were divided into the control group and the observation group.In the control group,25 cases were treated with chemotherapy combined with DC-CIK,and other 25 cases of observation group were treated with rituximab based on control group.The clinical curative effect and adverse reaction of the two groups were compared,and three-year survival rate of the two groups were followed up and recorded.Results After treatment,the expression of per2,BMAL1 and EVI1 mRNA in the two groups was significantly lower than that in the control group(P<0.05).Compared with the control group,the clinical effect of the observation group was slightly better,but its adverse reactions were more.The 3-year event-free survival rate in the observation group was higher than that in the control group.Conclusions The efficacy of rituximab combined with DC-CIK is better,and rituximab can make the prognosis of DC-CIK better,but its side effects are more and the cost is higher.